Sign in
Taking people in ItalyPhase 1

Testing a Targeted Medicine in Adults With Rheumatoid Arthritis

Tests a targeted medicine in adults with rheumatoid arthritis, a joint disease.

Key facts

Who runs it
AbbVie Deutschland GmbH & Co. KG
Where
Ferrara, Pavia, Reggio Emilia, Rome, and Rozzano, ItalySee the 5 sitesAlso in 4 other countries, 8 sites
Registry title
A Study to Evaluate Targeted Therapies for Patients with Rheumatoid Arthritis
Status
Recruiting
Phase
Phase 1
People taking part
19 people, planned
Started
17 Jul 2026
Expected to end
25 Jan 2029
Type of study
Interventional
Record updated
1 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with rheumatoid arthritis. It studies targeted therapies.

Age
18 years or older
Sex
Men and women can join

Main reasons for not taking part

  • Healthy volunteers cannot join

Where in Italy

Also in 4 other countries, 8 sites

  • University Hospital Of FerraraFerrara, ItalyTaking people
  • Fondazione IRCCS Policlinico San MatteoPavia, ItalyTaking people
  • Azienda USL IRCCS di Reggio EmiliaReggio Emilia, ItalyTaking people
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCSRome, ItalyTaking people
  • Humanitas Mirasole S.p.A.Rozzano, ItalyTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Plain-language title
Testing a Targeted Medicine in Adults With Rheumatoid ArthritisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
1 September 2026